Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 1/20 | 0.61 |
| ▸ | DRD4 | P21917 | 1/20 | 0.61 |
| ▸ | DRD3 | P35462 | 1/20 | 0.61 |
| ▸ | HTR1B | P28222 | 3/20 | 0.55 |
| ▸ | HTR1D | P28221 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL21595615 | 0.98 | DRD2 (0.59) | DRD2DRD4DRD3HTR1BHTR1D | |
| Formic Acid SCHEMBL5073493 | 0.90 | DRD2 (0.56) | DRD2DRD4DRD3HTR1BHTR1D | |
| SCHEMBL18295382 | 0.85 | HTR1B (0.52) | DRD2DRD4DRD3HTR1BHTR1D | |
| Hydrochloric Acid SCHEMBL21595601 | 0.84 | HTR1B (0.50) | DRD2DRD4DRD3HTR1BHTR1D | |
| SCHEMBL13589881 | 0.84 | ALDH1A1 (0.63) | DRD2DRD4DRD3HTR1BHTR1D | |
| SCHEMBL21601465 | 0.84 | HTR1B (0.50) | DRD2DRD4DRD3HTR1BHTR1D | |
| SCHEMBL7348310 | 0.84 | HTR1B (0.50) | DRD2DRD4DRD3HTR1BHTR1D | |
| SCHEMBL3763682 | 0.83 | DRD2 (0.58) | DRD2DRD4DRD3ALDH1A1KDM4E | |
| SCHEMBL11444962 | 0.83 | DRD2 (0.59) | DRD2DRD4DRD3ALDH1A1LMNA | |
| Hydrochloric Acid SCHEMBL21595618 | 0.82 | HTR1B (0.49) | DRD2DRD4DRD3HTR1BHTR1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220119376-A1 | TRICYCLIC COMPOUNDS ACTING ON CRBN PROTEINS | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2022-04-21 | — | — | US | disclosed |
| EP-3848367-A1 | TRICYCLIC COMPOUNDS ACTING ON CRBN PROTEINS | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) | 2021-07-14 | — | — | EP | disclosed |
| WO-2019244066-A2 | PYRIDIN-3-YL ACETIC ACID DERIVATIVES AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV Healthcare UK (No.5) Limited (GB) | 2019-12-26 | — | — | WO | disclosed |
| US-20080312242-A1 | 7-ARYL-3, 9-DIAZABICYCLO(3.3.1)NON-6-ENE DERIVATIVES AND THEIR USE AS RENIN INHIBITORS IN THE TREATMENT OF HYPERTENSION, CARDIOVASCULAR OR RENAL DISEASES | ACTELION PHARMACEUTICALS, LTD. (CH) | 2008-12-18 | — | — | US | disclosed |
| US-7427613-B2 | 7-aryl-3,9-diazabicyclo(3.3.1)non-6-ene derivatives and their use as renin inhibitors in the treatment of hypertension, cardiovascular or renal diseases | ACTELION PHARMACEUTICALS LTD. (CH) | 2008-09-23 | — | — | US | disclosed |
| US-20050176700-A1 | 7-aryl-3,9-diazabicyclo(3.3.1)non-6-ene derivatives and their use as renin inhibitors in the treatment of hypertension,cardiovascular or renal diseases | ACTELION PHARMACEUTICALS LTD. (CH) | 2005-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220119376-A1 | TRICYCLIC COMPOUNDS ACTING ON CRBN PROTEINS | CRBN, CSNK2A1, CSNK2A2 | DRD2 4621/4885DRD4 4606/4885DRD3 4339/4885 |
| US-20050176700-A1 | 7-aryl-3,9-diazabicyclo(3.3.1)non-6-ene derivatives and their use as renin inhibitors in the treatment of hypertension,cardiovascular or renal diseases | REN, AGTR1, ACE | DRD2 2061/4885DRD4 2268/4885DRD3 966/4885 |
| US-20080312242-A1 | 7-ARYL-3, 9-DIAZABICYCLO(3.3.1)NON-6-ENE DERIVATIVES AND THEIR USE AS RENIN INHIBITORS IN THE TREATMENT OF HYPERTENSION, CARDIOVASCULAR OR RENAL DISEASES | REN, AGTR1, ACE | DRD2 2061/4885DRD4 2268/4885DRD3 966/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.